论文部分内容阅读
目的:研究冠心病患者微量白蛋白尿(MAU)与可溶性糖基化终产物受体(sRAGE)的关系。方法:纳入符合标准的149例患者,根据冠状动脉造影结果分为冠心病组(n=99)和非冠心病组(n=50);并将99例冠心病患者按照有无MAU分为冠心病MAU亚组(n=26)和冠心病非MAU亚组(n=73);比较各组间sRAGE的水平,并使用logstic回归进行分析,观察冠心病患者MAU与sRAGE的关系。结果:sRAGE各组间比较:冠心病组(732.6±133.2)明显低于非冠心病组(1055.5±279.5),冠心病MAU亚组(655.3±121.4)明显低于冠心病非MAU亚组(760.1±127.0),差异均有统计学意义(P均<0.001)。logistic回归分析显示:MAU与sRAGE明显负相关(P=0.018,95%可信区间0.992～0.999)。结论:冠心病患者MAU水平与sRAGE明显负相关,sRAGE可能是预测冠心病患者风险的新型生物标志物。
Objective: To study the relationship between microalbuminuria (MAU) and soluble receptor for advanced glycation end products (sRAGE) in patients with coronary heart disease. Methods: One hundred and ninety-nine patients were enrolled and divided into coronary heart disease group (n = 99) and non-coronary heart disease group (n = 50) according to coronary angiography results. Ninety-nine patients with coronary heart disease were divided into two groups according to the presence or absence of MAU The MAU subgroup of heart disease (n = 26) and non-MAU subgroup of coronary heart disease (n = 73) were compared. The levels of sRAGE in each group were compared and analyzed by logistic regression to observe the relationship between MAU and sRAGE in patients with coronary heart disease. Results: Compared with non-MAU subgroup of coronary heart disease (760.1), coronary heart disease group (732.6 ± 133.2) was significantly lower than non-coronary artery disease group (1055.5 ± 279.5), coronary artery disease subgroup MAU (655.3 ± 121.4) ± 127.0), the differences were statistically significant (P <0.001). Logistic regression analysis showed significant negative correlation between MAU and sRAGE (P = 0.018, 95% confidence interval 0.992-0.9999). Conclusion: There is a clear negative correlation between MAU level and sRAGE in patients with coronary heart disease. SRAGE may be a new biomarker to predict the risk of coronary heart disease.